Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

March 31, 2015

Conditions
Social Anxiety Disorder
Interventions
DRUG

PH94B

"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"

OTHER

Placebo

"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"

Trial Locations (1)

10128

The Medical Research Network, LLC, New York

Sponsors
All Listed Sponsors
lead

Pherin Pharmaceuticals, Inc.

INDUSTRY

NCT02622958 - Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) | Biotech Hunter | Biotech Hunter